Talimogene laherparepvec

N/A

Report date: 2026/02/18 20:02:09

Base Information

Drug NameTalimogene laherparepvec
Drug Alias Name拉赫-他利莫近Talimogenum laherparepvecum拉他莫基OncoVEX(GM-CSF)T-vec +[11] 
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Herpes simplex virus vector > HSV-1 vector
Mechanisms of ActionApoptosis stimulantsApoproteins stimulantsColony stimulating factor stimulants
TargetsApoproteinsColony stimulating factor
Therapy Area/IndicationsSolid tumoursHypospadiasPleural Neoplasms +[19] 
Global Approved IndicationsMelanoma
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2015/10/27
Country/TerritoryCzechiaBelgiumCanada +[24] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesAmgen Inc
China Registration ClassN/A

Develop Information

Active CompaniesThe Netherlands Cancer InstituteThe University Of IowaThe University Of Arizona +[7] 
Inactive CompaniesUniversity Of California San FranciscoThe University Of California DavisThe University Of Texas MD Anderson Cancer Center +[4] 
Active IndicationsSolid tumoursHypospadiasPancreatic Neoplasms +[12] 
Inactive IndicationsPleural NeoplasmsHead and Neck NeoplasmsInflammatory Breast Neoplasms +[7] 

Other Information

ATC CodeL01XL02
Related LinksWikipediaKEGG